Osteoporosis
Conditions
Interventions
Denosumab group:Desmodium subcutaneous injection 60 mg/6 months
Teriparatide group:Teriparatide subcutaneous injection 20ug/day
Sponsors
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Eligibility
Sex/Gender
All
Age
55 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with single-segment degenerative lumbar spinal stenosis undergoing surgery 2. Dual-energy X-ray detection of lumbar spine bone density and/or femoral neck bone density T value <= 2.5 3. Informed and agreed to participate in this clinical trial
Exclusion criteria
Exclusion criteria: 1. Spinal tumors 2. Spinal infection 3. Vertebral fractures 4. History of spinal surgery 5. History of anti-osteoporosis drug use 6. Severe spinal deformity 7. Other physical diseases, including diabetes, severe hypertension, autoimmune diseases, heart, liver and kidney diseases, malignant tumors, mental illness and other diseases that doctors believe may affect the test process 8. Exclude primary osteoporosis, any disease that affects bone metabolism or treatment response, including serum pTH>65pg/mI, 25-hydroxyvitamin D135U/L, history of bone tumors, Paget's disease, radiotherapy history 9. Allergic to teriparatide, denosumab or any excipients 10. Hyperparathyroidism, severe renal insufficiency, hypercalcemia, hypocalcemia and other contraindications to teriparatide and denosumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone fusion;Postoperative whole body bone mass and bone metabolism; | — |
Secondary
| Measure | Time frame |
|---|---|
| Loose screws;pain; | — |
Countries
China
Contacts
Public ContactGuodong Wang
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Outcome results
None listed